PTK2 and hepatocellular carcinoma: They also found that FAK inhibition caused previously unresponsive KPC mouse models to respond to T-cell-targeted immunotherapy and PD-1 antagonists, indicating that the TME can overcome the DR barrier for T-cell infiltration and the subsequent success of ICI treatment.76 This was further supported by a hepatocellular carcinoma (HCC) mouse model: FAK is highly expressed in human HCC and is associated with poor OS and progress-free survival (PFS) in HCC patients and showed the combination of a FAK inhibitor VS4718 and an anti-PD1 antibody had a better effect than monotherapy against HCC.77